PapersTrialsTopicsCompoundsCountriesStakeholdersPeopleCoursesEvents
Browse all papers

Latest papers

Long-term efficacy of psilocybin with adjunct psychotherapy in treatment-resistant depressionPsilocybin · Treatment-resistant depressionDrug-drug interactions between psychiatric medications and MDMA or psilocybinMDMA & psilocybin · SafetyAn international mega-analysis of psychedelic drug effects on brain circuit functionCross-compound · NeuroimagingEsketamine in treatment-resistant depression with and without comorbid borderline personalityEsketamine · Treatment-resistant depression

Featured

Road to Access

Science, regulation, and economics on the path to patient access.

01Evidence02Approval03Reimbursement04Delivery05Access—Big Picture
Start the journey
ResultsCompare outcome data across trials and publications.Research SnapshotOne-page overview of trials, participants, papers, and research networks.Clinical GuidelinesTrial-anchored manuals and protocol guidance with competency mapping.Research recapsMonthly evidence summaries with key takeaways.Map of researchLandscape view of trials, compounds, and outcomes.NewsletterWeekly or daily updates on trials, publications, analysis, and more.Research GroupsWorldwide map of psychedelic research centres by region.Research NetworkInteractive co-authorship map of psychedelic researchers.Top papersFind needles in the haystack of psychedelic research per topic.
AskBeta
Pricing
Back to journals
Academic JournalOpen Access

HRB Open Research

1 Papers Indexed in Blossom

Data updated June 16, 2026

Research Footprint

HRB Open Research has 1 tracked paper indexed in Blossom (2022) from 6 authors, most often covering Ketamine, across Anxiety Disorders, Depressive Disorders and Major Depressive Disorder (MDD).

Published Papers

Open Accessindividual

Ketamine as an adjunctive therapy for major depression - a randomised controlled pragmatic pilot trial (Karma-Dep Trial)

This first pragmatic randomised pilot trial of four once-weekly adjunctive ketamine infusions in hospitalised patients with major depression found the infusions were generally safe and well tolerated but produced no significant difference in HRSD-24 scores versus midazolam. The study indicates a definitive trial of adjunctive ketamine is feasible.

Published
January 27, 2022
Journal
HRB Open Research
Authors
Gallagher, B., Foley, M., Slattery, C. M., Gusciute, G., Shanahan, E., McLoughlin, D. M.

Quick Facts

Papers Indexed
1
h-Index
13
Open Access
Yes
Publisher
F1000 Research
Country
United Kingdom
Website
Visit

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.